New approach aims to tame dangerous transplant side effect
NCT ID NCT03680092
Summary
This study tested whether a new combination of two drugs (cyclophosphamide and abatacept) could better prevent a serious complication called graft-versus-host disease (GVHD) after stem cell transplants for blood cancers. GVHD happens when donor immune cells attack the patient's body. The trial compared this new approach to standard prevention methods in 43 patients who received transplants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.